Anat Polyachenko

Anat represents emerging to mature life sciences companies, as well as private equity and venture capital funds. She advises on a broad range of corporate and transactional affairs, including licensing transactions, collaboration agreements, strategic alliances, joint ventures, cross-border mergers and acquisitions and equity investments. Anat also handles contractual arrangements for drug discovery, research, development, manufacturing and supply, and commercialization of new products.

Licensing and Collaboration Agreements

• H. Lundbeck A/S in its collaboration with Rgenta Therapeutics to discover small molecules targeting RNA regulation and splicing of disease-causing genes.

• Astellas in its license agreement with ExCellThera for the in vitro use of certain molecules in the field of pluripotent stem cells (PSCs) and PSC-derived cells.

• H. Lundbeck A/S in the licensing to Denovo Biopharma of global rights to idalopirdine (an oral 5-HT6 antagonist) for Alzheimer's Disease, schizophrenia and other indications, subject to options for Lundbeck to re-acquire such rights with the parties sharing China rights.

Mergers and Acquisitions

• Bayer AG in its acquisition of drug discovery company Vividion Therapeutics for USD 1.5 billion upfront and up to USD 500 million in success-based milestone payments.

• Kite in the sale to BioNTech of their neoantigen TCR cell therapy R&D platform and manufacturing facility.

• Certified Information Privacy Professional US Private Sector (CIPP/US)
• New York State Bar Association - Member